专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20180110801A1 POLYSACCHARIDE-POLYAMINE COPOLYMER AND USE THEREOF IN REDUCING URIC ACID CONCENTRATION IN PLASMA 审中-公开
公开(公告)号：US20180110801A1
公开(公告)日：2018-04-26
申请号：US15559196
申请日：2016-03-18
申请人： Dazhi YANG
发明人： Dazhi YANG
IPC分类号： A61K31/785 , C08G83/00 , A61P7/08 , C08G81/00 , C08B15/06 , C08J9/16 , B01J20/26 , B01J20/28
CPC分类号： A61K31/785 , A61K9/14 , A61K31/738 , A61P7/08 , B01J20/264 , B01J20/267 , B01J20/28004 , B01J20/28078 , B01J20/28085 , B01J20/3085 , C08B15/06 , C08F251/02 , C08G73/0206 , C08G81/00 , C08G83/002 , C08G2101/00 , C08G2210/00 , C08J9/16 , C08J2205/022 , C08J2207/10 , C08J2387/00 , C08L1/08 , C08L3/20 , C08L5/02 , C08L5/08
摘要： Disclosed is a pharmaceutical composition for treating hyperuricemia (HUA). The pharmaceutical composition includes a polysaccharide-polyamine copolymer and a pharmaceutically acceptable salt thereof as active ingredients. The polysaccharide-polyamine copolymer is formed by copolymerization of the following two parts: a selectively oxidized polysaccharide with 2,3-dialdehydo, and a polyamine with an amino functional group; the polyamine with an amino functional group and the selectively oxidized polysaccharide with 2,3-dialdehydo can form a net structure by means of covalent crosslinking, resulting in a hydrogel with an amino functional group or a granular polysaccharide-polyamine copolymer, wherein the amino functional group in the hydrogel with an amino functional group or the granular polysaccharide-polyamine copolymer can be protonated so as to form a cationic copolymer of a three-dimensional network structure having a protonated site, and the nitrogen content of the cationic copolymer and the nitrogen content of the polysaccharide-polyamine copolymer are above 12.3 wt %, and both the cationic copolymer and the polysaccharide-polyamine copolymer are water-insoluble.

2. 发明申请

US20180071331A1 POLYSACCHARIDE-POLYAMINE COPOLYMER AND USE THEREOF IN REDUCING LOW DENSITY LIPOLIPOPROTEIN (LDL) CONCENTRATION IN PLASMA 审中-公开
公开(公告)号：US20180071331A1
公开(公告)日：2018-03-15
申请号：US15559221
申请日：2016-03-18
申请人： Dazhi YANG
发明人： Dazhi YANG
IPC分类号： A61K31/738 , A61K9/14
CPC分类号： A61K31/785 , A61K9/14 , A61K31/738 , A61P7/08 , B01J20/264 , B01J20/267 , B01J20/28004 , B01J20/28078 , B01J20/28085 , B01J20/3085 , C08B15/06 , C08F251/02 , C08G73/0206 , C08G81/00 , C08G83/002 , C08G2101/00 , C08G2210/00 , C08J9/16 , C08J2205/022 , C08J2207/10 , C08J2387/00 , C08L1/08 , C08L3/20 , C08L5/02 , C08L5/08
摘要： Disclosed is a pharmaceutical composition for treating hypercholesterolemia. The pharmaceutical composition includes a polysaccharide-polyamine copolymer and a pharmaceutically acceptable salt thereof as active ingredients. The polysaccharide-polyamine copolymer is formed by copolymerization of the following two parts: a selectively oxidized polysaccharide with 2,3-dialdehyde, and a polyamine with an amino functional group; the polyamine with an amino functional group and the selectively oxidized polysaccharide with 2,3-dialdehyde can form a net structure by means of covalent crosslinking, resulting in a hydrogel with an amino functional group or a granular polysaccharide-polyamine copolymer, wherein the amino functional group in the hydrogel with an amino functional group or the granular polysaccharide-polyamine copolymer can be protonated so as to form a cationic copolymer of a three-dimensional network structure having a protonated site, and the nitrogen content of the cationic copolymer and the nitrogen content of the polysaccharide-polyamine copolymer are above 12.3 wt %, and both the cationic copolymer and the polysaccharide-polyamine copolymer are water-insoluble.

3. 发明授权

US09782490B2 Method for crosslinking hyaluronic acid; method for preparing an injectable hydrogel; hydrogel obtained; use of the obtained hydrogel 有权
公开(公告)号：US09782490B2
公开(公告)日：2017-10-10
申请号：US14896504
申请日：2014-06-10
申请人： ANTEIS S.A.
发明人： Bénédicte Vincente Tauzin
IPC分类号： A61K31/167 , A61K47/48 , A61K8/02 , A61K9/00 , C08B37/08 , A61L27/20 , A61K8/73 , A61Q19/08 , A61K8/04 , C08J3/075 , C08L5/08 , A61K31/728 , C08J3/24 , A61L27/52 , A61L27/54 , A61K31/738 , A61Q19/00
CPC分类号： A61K47/6903 , A61K8/0216 , A61K8/042 , A61K8/735 , A61K9/0019 , A61K31/167 , A61K31/728 , A61K31/738 , A61K47/61 , A61K2800/40 , A61K2800/57 , A61K2800/91 , A61K2800/95 , A61L27/20 , A61L27/52 , A61L27/54 , A61L2300/402 , A61L2400/06 , A61L2430/34 , A61Q19/00 , A61Q19/08 , C08B37/0072 , C08J3/075 , C08J3/244 , C08J3/247 , C08J2305/08 , C08L5/08 , A61K2300/00
摘要： The present invention relates to a method for crosslinking hyaluronic acid, a method for preparing an injectable hydrogel, the hydrogel thus obtained and its use.

4. 发明申请

US20170224613A1 HYDROGEL COMPOSITIONS, METHODS FOR PREPARING THE SAME AND USES THEREOF 审中-公开
公开(公告)号：US20170224613A1
公开(公告)日：2017-08-10
申请号：US15515409
申请日：2014-09-30
申请人： CHONGQING MJ MEDICAL DEVICES CO., LTD.
发明人： Jun WU , Gaoxing LUO , Johnson Yiu-Nam LAU , Manson FOK , Chun-Ho WONG , Meinrad FLURY , Benjamin Tak-Kwong LEE
IPC分类号： A61K9/00 , A61K9/06 , A61K47/36 , A61K31/736 , A61K31/738 , A61K9/51 , A61K31/045
CPC分类号： A61K9/0014 , A61K9/06 , A61K9/5161 , A61K31/045 , A61K31/736 , A61K31/738 , A61K47/36 , A61K2300/00
摘要： Disclosed are hydrogel composition, method for preparing the same and use thereof. The hydrogel composition comprises a guar gum derivative which is crosslinked, a mint-based component, water, and optionally, an amphiphilic core-shell nanoparticle having a hydrophobic core and a hydrophilic shell, wherein the amount of the mint-based component is in the range of 1-6 wt % and the amount of the water is in the range of 65-95 wt %, based on the total weight of the hydrogel composition. The hydrogel composition is safe and can provide symptomatic relief for patients with symptoms such as severe and intractable pruritus associated with hypertrophic scars. The symptomatic relief effect of the hydrogel composition is reproducible, and is independent of the etiology of the burn trauma, extent of the scarring and duration of the scar formation, while tachyphylaxis is not observed. Also disclosed is a medical device comprising the hydrogel composition.

5. 发明授权

US09687501B2 Modified starch material of biocompatible hemostasis 有权
公开(公告)号：US09687501B2
公开(公告)日：2017-06-27
申请号：US13894396
申请日：2013-05-14
申请人： Xin Ji , Cheng Xing , Xueshen Shi , Jianping Chen
发明人： Xin Ji , Cheng Xing , Xueshen Shi , Jianping Chen
IPC分类号： A61K31/718 , A61L24/00 , A61L26/00 , A61K9/14 , C08L3/18 , C08L3/04 , C08L89/06 , C08B31/12 , C08B31/08 , C08B31/02 , C08B33/04 , C08B31/10 , C08B31/16 , C08B35/02 , C08B33/06 , C08B35/06 , C08B35/04 , C08B33/02 , C08B31/04 , C08B30/20 , C08B31/00 , C08B30/00 , A61K31/738 , A61L24/08 , A61K45/06 , A61K9/19 , C08B31/06 , A61K9/00
CPC分类号： A61L31/042 , A61K9/0014 , A61K9/14 , A61K9/19 , A61K31/718 , A61K31/738 , A61K45/06 , A61L24/0015 , A61L24/0036 , A61L24/0073 , A61L24/08 , A61L24/104 , A61L26/0023 , A61L26/0085 , A61L31/045 , A61L31/125 , A61L2300/406 , A61L2400/04 , A61L2430/34 , C08B30/00 , C08B30/20 , C08B31/00 , C08B31/003 , C08B31/02 , C08B31/04 , C08B31/08 , C08B31/10 , C08B31/12 , C08B31/16 , C08B33/02 , C08B33/04 , C08B33/06 , C08B35/02 , C08B35/04 , C08B35/06 , C08L3/04 , C08L3/18 , C08L89/06 , Y10T428/2982
摘要： A modified starch material is arranged for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

6. 发明申请

US20170151367A1 DRY DERMAL FILLER COMPOSITIONS AND METHODS OF RECONSTITUTION 审中-公开
公开(公告)号：US20170151367A1
公开(公告)日：2017-06-01
申请号：US15428985
申请日：2017-02-09
申请人： Allergan, Inc.
发明人： Xiaojie Yu , Jacob F. Pollock , Nicholas Manesis
IPC分类号： A61L27/20 , A61L27/54 , A61L27/52 , A61L27/50
CPC分类号： A61L27/20 , A61K8/41 , A61K8/42 , A61K8/735 , A61K9/0024 , A61K31/137 , A61K31/167 , A61K31/728 , A61K31/738 , A61K45/06 , A61K47/36 , A61K2800/31 , A61K2800/91 , A61L27/50 , A61L27/52 , A61L27/54 , A61L2300/402 , A61L2300/43 , A61L2300/436 , A61L2300/45 , A61L2400/06 , A61L2430/34 , A61Q19/08 , A61K2300/00 , C08L5/08
摘要： Dermal fillers are provided, particularly hyaluronic acid-based dermal fillers containing additives, for example, unstable additives, the dermal fillers being provided in an anhydrous state for extended shelf life.

7. 发明授权

US09375447B2 Modified hyaluronan and uses thereof in cancer treatment 有权
标题翻译：改性透明质酸及其在癌症治疗中的用途
公开(公告)号：US09375447B2
公开(公告)日：2016-06-28
申请号：US13826952
申请日：2013-03-14
申请人： National Cheng Kung University
发明人： Nan-Shan Chang , Wan-Pei Su
IPC分类号： A61K31/738 , A61K39/395 , C08B37/08 , A61K31/728 , C07K16/44
CPC分类号： A61K31/738 , A61K31/728 , A61K39/3955 , C07K16/44 , C08B37/0072
摘要： Uses of depolymerized hyaluronan (e.g., prepared by sonicating high molecular weight hyaluronan such as naturally-occurring hyaluronan) or anti-Hyal-2 antibody in cancer treatment. Also described herein are methods for preparing depolymerized and crosslinked hyaluronan by sonication and the hyaluronan composition thus obtained.
摘要翻译：使用解聚的透明质酸（例如，通过在高分子量透明质酸例如天然存在的透明质酸中进行超声处理）或抗Hyal-2抗体在癌症治疗中的应用。本文还描述了通过超声处理制备解聚和交联的透明质酸的方法和由此获得的透明质酸组合物。

8. 发明申请

US20150359721A1 INCREASING MUSCULAR VOLUME IN A HUMAN USING HYALURONIC ACID 有权
标题翻译：使用羟丙酸在人体中增加肌肉量
公开(公告)号：US20150359721A1
公开(公告)日：2015-12-17
申请号：US14761793
申请日：2013-04-19
申请人： Jeffrey Hagel , Damian Naqvi
发明人： Jeffrey Hagel , Damian Naqvi
IPC分类号： A61K8/73 , A61Q19/00 , A61K9/00 , A61K31/728 , A61K31/738
CPC分类号： A61K8/735 , A61K9/0019 , A61K31/728 , A61K31/738 , A61K2800/74 , A61K2800/91 , A61Q19/00
摘要： A method for increasing muscular volume of a muscle in a human is provided. The method comprises injecting a composition comprising hyaluronic acid (HA) into one or more than one location of a muscle, thereby increasing the muscular volume as compared to before the injection. The muscle may be an arm, leg, chest, back or buttock muscle, or any other desired muscle. A method for altering a contour of a muscle in a human is also provided, which comprises obtaining an image of the contour of the muscle, determining a new contour, injecting an HA composition into one or more than one location of the muscle to obtain the new contour, thereby altering the contour as compared to before the injection. A use of a composition comprising HA for increasing muscular volume of a muscle in a human is also provided, where the composition is for injection into muscle.
摘要翻译：提供了一种增加人体肌肉体积的方法。该方法包括将包含透明质酸（HA）的组合物注射到肌肉的一个或多于一个位置，从而与注射之前相比增加肌肉体积。肌肉可能是手臂，腿部，胸部，背部或臀部肌肉，或任何其他所需的肌肉。还提供了一种用于改变人体肌肉轮廓的方法，其包括获得肌肉轮廓的图像，确定新轮廓，将HA组合物注射到肌肉的一个或多于一个位置以获得新轮廓，从而与注射前相比改变轮廓。还提供使用组合物，其包含HA用于增加人体肌肉的体积，其中组合物用于注射到肌肉中。

9. 发明申请

US20150297492A1 DRY DERMAL FILLER COMPOSITIONS AND METHODS OF RECONSTITUTION 审中-公开
标题翻译：干燥填充剂组合物和重建方法
公开(公告)号：US20150297492A1
公开(公告)日：2015-10-22
申请号：US14693628
申请日：2015-04-22
申请人： Allergan, Inc.
发明人： Xiaojie Yu , Jacob F. Pollock , Nicholas Manesis
IPC分类号： A61K8/73 , A61K8/41 , A61Q19/00 , A61K8/42
CPC分类号： A61L27/20 , A61K8/41 , A61K8/42 , A61K8/735 , A61K9/0024 , A61K31/137 , A61K31/167 , A61K31/728 , A61K31/738 , A61K45/06 , A61K47/36 , A61K2800/31 , A61K2800/91 , A61L27/50 , A61L27/52 , A61L27/54 , A61L2300/402 , A61L2300/43 , A61L2300/436 , A61L2300/45 , A61L2400/06 , A61L2430/34 , A61Q19/08 , A61K2300/00 , C08L5/08
摘要： Dermal fillers are provided, particularly hyaluronic acid-based dermal fillers containing additives, for example, unstable additives, the dermal fillers being provided in an anhydrous state for extended shelf life.
摘要翻译：提供皮肤填充剂，特别是含有添加剂的透明质酸类皮肤填充剂，例如不稳定添加剂，以无水状态提供皮肤填充剂以延长保质期。

10. 发明申请

US20150283169A1 PHARMACEUTICAL AGENT HAVING LONG-LASTING EFFECT OF TREATING ARTHRITIC DISORDERS 审中-公开
标题翻译：具有治疗神经疾病长期作用的药物代理
公开(公告)号：US20150283169A1
公开(公告)日：2015-10-08
申请号：US14509736
申请日：2014-10-08
申请人： SEIKAGAKU CORPORATION
发明人： Kenji MIYAMOTO
IPC分类号： A61K31/728 , A61K9/00 , A61K31/738
CPC分类号： A61K31/728 , A61K9/0019 , A61K9/06 , A61K31/738 , A61K47/02 , C08B37/0072
摘要： The present invention relates to an injection solution for intra-articular administration for treating arthritic disorders comprising a cross-linked hyaluronic acid derivative wherein part of functional groups of a hyaluronic acid are cross-linked with a cross-linking group to the extent of 0.6 to 15% of cross-linking extent as an active ingredient in an amount having a long-lasting analgesic effect and a pharmaceutically acceptable carrier, and an analgesic composition for suppressing a cartilage degeneration caused by arthritic disorders or a composition for suppressing a cartilage degeneration or an inflammation of synovium caused by arthritic disorders each comprising the cross-linked hyaluronic acid derivative and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及用于治疗关节炎疾病的关节内给药的注射液，其包含交联的透明质酸衍生物，其中透明质酸的官能团的一部分与交联基团交联至0.6〜具有持久镇痛效果的量的作为活性成分的交联程度的15％和药学上可接受的载体，以及用于抑制由关节炎病症引起的软骨退化的镇痛组合物或用于抑制软骨退化的组合物或由关节炎病症引起的滑膜的炎症各自包含交联的透明质酸衍生物和药学上可接受的载体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式